Early and 1-year outcomes of aortic root surgery in patients with Marfan syndrome: A prospective, multicenter, comparative study

详细信息    查看全文

• 作者：Joseph S. Coselli ; MD^a ; Irina V. Volguina ; PhD^a ; ^{volguina@bcm.edu" class="auth_mail} ; Scott A. LeMaire ; MD^a ; Thoralf M. Sundt ; MD^b ; Heidi M. Connolly ; MD^c ; Elizabeth H. Stephens ; MD ; PhD^d ; Hartzell V. Schaff ; MD^e ; Dianna M. Milewicz ; MD ; PhD^f ; Luca A. Vricella ; MD^g ; Harry C. Dietz ; MD^h ; Charles G. Minard ; PhDⁱ ; D. Craig Miller ; MD^d ; on behalf of the Aortic Valve Operative Outcomes in Marfan Patients Study Group
• 关键词：26 ; 35
• 刊名：The Journal of Thoracic and Cardiovascular Surgery
• 出版年：June 2014
• 年：2014
• 卷：147
• 期：6
• 页码：1758-1767.e4
• 全文大小：524 K

文摘

To compare the 1-year results after aortic valve-sparing (AVS) or valve-replacing (AVR) aortic root replacement from a prospective, international registry of 316 patients with Marfan syndrome (MFS).

Methods

Patients underwent AVS (n = 239, 76%) or AVR (n = 77, 24%) aortic root replacement at 19 participating centers from 2005 to 2010. One-year follow-up data were complete for 312 patients (99%), with imaging findings available for 293 (94%). The time-to-events were compared between groups using Kaplan-Meier curves and Cox proportional hazards models.

Results

Two patients (0.6%)—1 in each group—died within 30 days. No significant differences were found in early major adverse valve-related events (MAVRE; P = .6). Two AVS patients required early reoperation for coronary artery complications. The 1-year survival rates were similar in the AVR (97%) and AVS (98%) groups; the procedure type was not significantly associated with any valve-related events. At 1 year and beyond, aortic regurgitation of at least moderate severity (≥2+) was present in 16 patients in the AVS group (7%) but in no patients in the AVR group (P = .02). One AVS patient required late AVR.

Conclusions

AVS aortic root replacement was not associated with greater 30-day mortality or morbidity rates than AVR root replacement. At 1 year, no differences were found in survival, valve-related morbidity, or MAVRE between the AVS and AVR groups. Of concern, 7% of AVS patients developed grade ≥2+ aortic regurgitation, emphasizing the importance of 5 to 10 years of follow-up to learn the long-term durability of AVS versus AVR root replacement in patients with MFS.